In a clinical study of healthy adults, Dyanavel XR tablets were deemed to be bioequivalent to amphetamine extended-release oral suspension in patients with attention-deficit/hyperactivity disorder (ADHD) by the US Food and Drug Administration (FDA).
Ashley Gallagher
Advertisement
Articles by Ashley Gallagher
Advertisement
Latest Updated Articles
FDA approves Dyanavel XR for ADHD treatment in kids 6 and olderPublished: November 5th 2021 | Updated:
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Health system–based clinical pathway improves pediatric lipid screening rates
2
FDA approves linaclotide (Linzess) for pediatric patients aged 7 years and older with IBS-C
3
Wesley Kufel, PharmD, discusses doxycycline for post-exposure prevention of Lyme disease in young children
4
Prenatal COVID-19 exposure linked to adverse neurodevelopment in offspring
5
